Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.

Zhang D, Lu Y, Liu K, Liu B, Wang J, Zhang G, Zhang H, Liu Y, Wang B, Zheng M, Fu L, Hou Y, Gong N, Lv Y, Li C, Cooper CB, Upton AM, Yin D, Ma Z, Huang H.

J Med Chem. 2012 Oct 11;55(19):8409-17. doi: 10.1021/jm300828h.

PMID:
22931472
2.

Synthesis and biological evaluation of novel 2-methoxypyridylamino-substituted riminophenazine derivatives as antituberculosis agents.

Zhang D, Liu Y, Zhang C, Zhang H, Wang B, Xu J, Fu L, Yin D, Cooper CB, Ma Z, Lu Y, Huang H.

Molecules. 2014 Apr 9;19(4):4380-94. doi: 10.3390/molecules19044380.

3.

Systematic evaluation of structure-activity relationships of the riminophenazine class and discovery of a C2 pyridylamino series for the treatment of multidrug-resistant tuberculosis.

Liu B, Liu K, Lu Y, Zhang D, Yang T, Li X, Ma C, Zheng M, Wang B, Zhang G, Wang F, Ma Z, Li C, Huang H, Yin D.

Molecules. 2012 Apr 17;17(4):4545-59. doi: 10.3390/molecules17044545.

4.

[A study on the activity of clofazimine with antituberculous drugs against Mycobacterium tuberculosis].

Lu Y, Wang B, Zhao WJ, Zheng MQ, Li P, Fu L, Liang BW.

Zhonghua Jie He He Hu Xi Za Zhi. 2010 Sep;33(9):675-8. Chinese.

PMID:
21092635
5.

Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation.

Lu Y, Zheng M, Wang B, Fu L, Zhao W, Li P, Xu J, Zhu H, Jin H, Yin D, Huang H, Upton AM, Ma Z.

Antimicrob Agents Chemother. 2011 Nov;55(11):5185-93. doi: 10.1128/AAC.00699-11.

6.

In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters.

Xu J, Lu Y, Fu L, Zhu H, Wang B, Mdluli K, Upton AM, Jin H, Zheng M, Zhao W, Li P.

Int J Tuberc Lung Dis. 2012 Aug;16(8):1119-25. doi: 10.5588/ijtld.11.0752.

PMID:
22691726
7.

Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies.

Jagannath C, Reddy MV, Kailasam S, O'Sullivan JF, Gangadharam PR.

Am J Respir Crit Care Med. 1995 Apr;151(4):1083-6.

PMID:
7697235
8.

Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.

Gopal M, Padayatchi N, Metcalfe JZ, O'Donnell MR.

Int J Tuberc Lung Dis. 2013 Aug;17(8):1001-7. doi: 10.5588/ijtld.12.0144. Review.

10.
11.

Synthesis and anti-tubercular activity of novel alkyl substituted riminophenazine derivatives.

Li YL, Zhang CL, Zhang DF, Lu Y, Wang B, Zheng MQ, Li C, Yin DL, Huang HH.

Yao Xue Xue Bao. 2012 Jun;47(6):745-54.

PMID:
22919722
12.

Antituberculosis activities of clofazimine and its new analogs B4154 and B4157.

Reddy VM, Nadadhur G, Daneluzzi D, O'Sullivan JF, Gangadharam PR.

Antimicrob Agents Chemother. 1996 Mar;40(3):633-36.

13.

Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China.

Tang S, Yao L, Hao X, Liu Y, Zeng L, Liu G, Li M, Li F, Wu M, Zhu Y, Sun H, Gu J, Wang X, Zhang Z.

Clin Infect Dis. 2015 May 1;60(9):1361-7. doi: 10.1093/cid/civ027.

15.

In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide.

Villar R, Vicente E, Solano B, Pérez-Silanes S, Aldana I, Maddry JA, Lenaerts AJ, Franzblau SG, Cho SH, Monge A, Goldman RC.

J Antimicrob Chemother. 2008 Sep;62(3):547-54. doi: 10.1093/jac/dkn214.

16.

Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.

Lilienkampf A, Mao J, Wan B, Wang Y, Franzblau SG, Kozikowski AP.

J Med Chem. 2009 Apr 9;52(7):2109-18. doi: 10.1021/jm900003c.

PMID:
19271749
17.

In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.

Lu J, Yue J, Wu J, Luo R, Hu Z, Li J, Bai Y, Tang Z, Xian Q, Zhang X, Wang H.

Pharmacology. 2010;85(6):365-71. doi: 10.1159/000299795.

PMID:
20530976
18.

In vitro investigation of the antimicrobial activities of novel tetramethylpiperidine-substituted phenazines against Mycobacterium tuberculosis.

van Rensburg CE, Jooné GK, Sirgel FA, Matlola NM, O'Sullivan JF.

Chemotherapy. 2000 Jan-Feb;46(1):43-8.

PMID:
10601797
19.

Ring-substituted imidazoles as a new class of anti-tuberculosis agents.

Gupta P, Hameed S, Jain R.

Eur J Med Chem. 2004 Sep;39(9):805-14.

PMID:
15337293
20.

[Recent progress in mycobacteriology].

Okada M, Kobayashi K.

Kekkaku. 2007 Oct;82(10):783-99. Japanese.

PMID:
18018602
Items per page

Supplemental Content

Support Center